The Valley Desk

NCT01667679 · Interventional trial

Efficacy and Safety of 20 mg Sumatriptan Powder Delivered Intranasally With the Bi-directional Device Compared With 100 mg Sumatriptan Tablets in Adults With Acute Migraine With or Without Aura

Overall registry status Completed

Phase 3

Conditions Headaches, Migraine

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov